Treats acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. ANDA 75383, held by Hospira. Cytarabine.
As of Nov 16, 2026, ANDA 75383 (Cytarabine), held by Hospira, was first approved by FDA on Nov 22, 1999, with 7 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Cytarabine Injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of Cytarabine Injection (preservative free preparations only) is indicated in the prophylaxis and treatment of meningeal leukemia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 22, 1999 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cytarabine100MG/ML · injectable;injection | Cytarabine | Rx |
| Aug 3, 2026 | Supplement 24Labeling · Standard review | Approved | None posted |
| Jun 2, 2020 | Supplement 18Labeling · Standard review | Approved | None posted |
| Jan 15, 2019 | Supplement 17Labeling · Standard review | Approved | None posted |
| Oct 3, 2018 | Supplement 15Labeling · Standard review | Approved | None posted |
| May 14, 2001 | Supplement 4Manufacturing | Approved | None posted |
| Nov 28, 2000 | Supplement 2Manufacturing | Approved | None posted |
| Oct 17, 2000 | Supplement 1Manufacturing | Approved | None posted |
| Nov 22, 1999 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters